Know Cancer

forgot password

Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)

Phase 1/Phase 2
18 Years
Open (Enrolling)
Metastatic Breast Cancer

Thank you

Trial Information

Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)

Inclusion Criteria:

Subjects must satisfy all of the following criteria to be included in the study:

1. Women ≥ 18 years old.

2. Histologically or cytologically confirmed adenocarcinoma of the breast with
metastatic disease and at least 1 measurable lesion per Response Evaluation Criteria
in Solid Tumors (RECIST) guidelines Version 1.1.

3. Documented HER2+ disease as measured by FISH or IHC (3+). See Appendix 17.8 for
documentation criteria.

4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

5. Hematological function, as follows:

- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

- Platelet count >100 x 109/L

- Hemoglobin ≥9 g/dL.

6. Renal function, as follows:

- Calculated creatinine clearance ≥60 mL/min using the modified Cockcroft Gault

7. Hepatic function, as follows:

- AST ≤2.5 x ULN (if liver metastases are present, < 5 x ULN)

- ALT ≤2.5 x ULN (if liver metastases are present, < 5 x ULN)

- Alkaline phosphatase ≤ 2.0 x ULN (if bone or liver metastases are present, < 5
x ULN)

- Bilirubin ≤1.5 x ULN.

8. Prothrombin time (PT) and partial thromboplastin time (PTT) ≤1.5 x ULN.

9. Availability of archived tumor sample or fresh tumor specimen (does not have to be
provided by treatment start) to confirm HER2 status and for tumor biomarkers/mutation

10. Subjects must be postmenopausal (no menstrual period for a minimum of 12 months) or
surgically sterile, or must use maximally effective birth control during the period
of therapy, and be willing to use contraception for 6 months following the last
investigational drug dose and have a negative urine or serum pregnancy test upon
entry into this study if subject is of childbearing potential. Partners of subjects
must be surgically sterile or willing to use a double barrier contraception method
upon enrollment, during the course of the study, and for 6 months after last
investigational drug dose received.

11. Subjects must be willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.

12. Subjects must be competent and able to comprehend, sign, and date an IEC- or
IRB-approved ICF before performance of any study specific procedures or tests.

Exclusion Criteria:

Subjects who meet any of the following criteria will be disqualified from entering the

1. Prior treatment for metastatic disease other than radiation therapy.
Neoadjuvant/adjuvant therapy with paclitaxel, and/or docetaxel, and/or trastuzumab is
allowed if completed more than 12 months prior to relapse/progression.

2. Clinically active brain metastases, defined as untreated symptomatic, or requiring
therapy with steroids or anticonvulsants to control associated symptoms. Subjects
with treated brain metastases that are no longer symptomatic and require no treatment
with steroids or anticonvulsants may be included in the study if they have recovered
from the acute toxic effect of radiotherapy.

3. LVEF < 50%. History of LVEF decline to < 50% on prior trastuzumab therapy.

4. Therapeutic or palliative radiation therapy or major surgery within 4 weeks before
study drug treatment.

5. History of other malignancies, except adequately treated nonmelanoma skin cancer,
curatively treated in situ cancer, or other solid tumors curatively treated with no
evidence of disease for ≥ 5 years.

6. Uncontrolled hypertension (diastolic blood pressure > 100 mmHg or systolic blood
pressure > 140 mmHg). Use of antihypertensive medications is permissible to maintain
blood pressure within the required parameters.

7. Clinically significant electrocardiogram (ECG) changes that obscure the ability to
assess the RR, PR, QT, QTc and QRS intervals.

8. Subjects with left bundle branch block, atrial fibrillation and use of a cardiac
pacemaker specifically will be excluded.

9. Ascites or pleural effusion requiring chronic medical intervention.

10. Pre-existing peripheral neuropathy > grade 1.

11. Myocardial infarction, symptomatic CHF (New York Heart Association > Class II),
unstable angina, or unstable cardiac arrhythmia requiring medication within 1 year
before enrollment.

12. Use of cytochrome P450 (CYP) 3A4 (CYP3A4) or CYP2C8 inducers within 28 days prior to
Day 1, use of CYP3A4 or CYP2C8 inhibitors within 14 days prior to Day 1, or
concurrent use of CYP3A4 or CYP2C8 inducers or inhibitors (see Appendix 17.6 for list
of CYP34A and CYP2C8 inhibitors and inducers).

13. Use of amiodarone within 6 months prior to enrollment.

14. Concurrent use of antiarrhythmic medications.

15. Participated in clinical drug studies within 4 weeks (2 weeks for small molecule
tyrosine kinase inhibitors; 6 weeks for mitomycin C and nitrosoureas) before study
drug treatment. Current participation in other investigational protocols or

16. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.

17. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C

18. History of hypersensitivity to any of the study drugs or to any excipients.

19. Serious intercurrent medical or psychiatric illnesses or any other conditions that in
the opinion of the Investigator would impair the ability to give informed consent or
unacceptably reduce protocol compliance or safety of the study treatment.

20. Pregnant, breastfeeding, or unwilling/unable to use acceptable contraception.

21. QTc interval > 450 msec by Friderica's formula on two successive screening
measurements (second measurement is required if first measurement is > 450 msec.

22. Personal or family history of long-QT syndrome.

23. Subjects who are receiving drugs that may affect QTc (eg, quinidine or moxifloxacin).

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Determination of the maximum tolerated dose based on the incidence of dose limiting toxicities (phase 1b only)

Outcome Description:

The following criteria will also be considered a dose limiting toxicity (DLT). > 15% decrease in left ventricular ejection fraction (LVEF) from baseline or an LVEF value > 10% below lower limit of normal (LLN) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x the upper limit of normal (ULN) AND total bilirubin > 2 x ULN or international normalized ratio (INR) > 1.5

Outcome Time Frame:

Study start to approximately 16 weeks

Safety Issue:



Argentina: Ministry of Health

Study ID:




Start Date:

January 2012

Completion Date:

May 2014

Related Keywords:

  • Metastatic Breast Cancer
  • U3-1287
  • Trastuzumab
  • Paclitaxel
  • newly diagnosed HER-2 positive
  • breast cancer
  • metastatic
  • Breast Neoplasms